Trial reportInternational journal of clinical pharmacy2013
Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
Trial report in International journal of clinical pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacist services for non-hospitalised patients.The Cochrane database of systematic reviews · 2018Pooled it
- Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial.BMC musculoskeletal disorders · 2016Trial
- Application of comprehensive pharmaceutical care program in identifying and addressing drug-related problems in hospitalized patients with osteoporosis.BMC health services research · 2022Article
- Article
- Impact of Pharmacist-Physician Collaboration on Osteoporosis Treatment Rates.The Annals of pharmacotherapy · 2018Article
- Exploring the current and future role of the pharmacists in osteoporosis screening and management in Malaysia.International journal of clinical pharmacy · 2018Article
- Clinical Outcomes Used in Clinical Pharmacy Intervention Studies in Secondary Care.Pharmacy (Basel, Switzerland) · 2017Article
- The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review.Patient preference and adherence · 2016Review
- Instructing students to measure their own bone density and prepare a simulated health class during pharmacy school improves their awareness and understanding of osteoporosis prevention.Journal of pharmaceutical health care and sciences · 2016Article
- The development and validation of the Satisfaction Questionnaire for Osteoporosis Prevention in Malaysia.Patient preference and adherence · 2014Article
- Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?Journal of translational medicine · 2013Review
- Osteoporosis: are healthcare professionals missing an opportunity.SpringerPlus · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study describes the analysis of secondary outcomes from a previously published randomised controlled trial, which assessed the effects of pharmaceutical care on medication adherence, persistence and bone turnover markers. The main focus of this manuscript is the effect of the provision of pharmaceutical care on these secondary outcomes, and details on the design of the intervention provided, the osteoporosis care plan and materials used to deliver the intervention.
objectivesTo evaluate the effects of pharmaceutical care on knowledge, quality of life (QOL) and satisfaction of postmenopausal osteoporotic women prescribed bisphosphonates, and their associating factors.
settingRandomised controlled trial, performed at an osteoporosis clinic of a tertiary hospital in Malaysia.
methodsPostmenopausal women diagnosed with osteoporosis (T-score ≤-2.5/lowtrauma fracture), just been prescribed weekly alendronate/risedronate were randomly allocated to receive intervention or standard care (controls). Intervention participants received a medication review, education on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects and the importance of medication adherence at months 0, 3, 6 and 12. MAIN OUTCOMES MEASURE: Knowledge, QOL and satisfaction.
resultsA total of 198 postmenopausal osteoporotic women were recruited: intervention = 100 and control = 98. Intervention participants reported significantly higher knowledge scores at months 3 (72.50 vs. 62.50 %), 6 (75.00 vs. 65.00 %) and 12 (78.75 vs. 68.75 %) compared to control participants. QOL scores were also lower (which indicates better QOL) at months 3 (29.33 vs. 38.41), 6 (27.50 vs. 36.56) and 12 (27.53 vs. 37.56) compared to control participants. Similarly, satisfaction score was higher in intervention participants (93.67 vs. 84.83 %). More educated women, with back pain, who were provided pharmaceutical care had better knowledge levels. Similarly, older, more educated women, with previous falls and back pain tend to have poorer QOL, whilst women who exercised more frequently and were provided pharmaceutical care had better QOL. Satisfaction also increased as QOL increases and when provided pharmaceutical care.
conclusionThe provision of pharmaceutical care improved knowledge, QOL and satisfaction in Malaysian postmenopausal osteoporotic women, showing that pharmacists have the potential to improve patients' overall bone health. Policymakers should consider placing a clinical pharmacist in the osteoporosis clinic to provide counselling to improve these outcomes.
Indexed as
Identifiers
23677816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.